Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial
Authors Fonseca ALA, Panetta H, Nascimento MA, Lira RPC, Arieta CEL
Received 3 May 2019
Accepted for publication 2 July 2019
Published 9 August 2019 Volume 2019:13 Pages 1523—1531
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Andre Luis A Fonseca, Heitor Panetta, Mauricio A Nascimento, Rodrigo Pessoa C Lira, Carlos Eduardo L Arieta
Department of Ophthalmology, State University of Campinas, Campinas, São Paulo, Brazil
Purpose: To determine the effect of short-term 4 mg/mL dexamethasone solution treatment in diabetic macular edema (DME).
Patients and methods: Twenty-seven pseudophakic diabetic patients with visual impairment caused by DME were randomized to receive 0.01 mL (40 μg), 0.03 mL (120 μg) or 0.05 mL (200 μg) intravitreal dexamethasone solution. Eyes were evaluated in terms of macular thickness, best-corrected visual acuity (BCVA) and intraocular pressure (IOP) at 3, 7 and 28 days after injection (D).
Results: There was a significant reduction in macular thickness between D0 and D3 for all groups (0.01 mL – P=0.008, 0.03 mL – P=0.038, and 0.05 mL – P=0.008). Between D0 and D7, a significant reduction in macular thickness was observed in 0.01 mL and 0.05 mL groups (0.01 mL – P=0.013 and 0.05 mL – P=0.021). Between D0 and D28, no significant reduction of macular thickness was observed for any group. Between D0 and D3, a significant improvement in BCVA in the 0.03 mL group (P=0.028) was observed. Between D0 and D7, a significant improvement in BCVA was observed in 0.01 mL and 0.03 mL groups (0.01 mL – P=0.018 and 0.03 mL – P=0.027). Between D0 and D28, a significant improvement in BCVA was observed for the 0.01 mL group (P=0.017). No significant differences in IOP measurements were observed for any group. Safety analysis revealed no serious ocular or systemic events.
Conclusion and relevance: Intravitreal dexamethasone solution is effective in reducing macular thickness secondary to DME in the short-term. Improvement in short-term visual acuity was observed. Although DME requires long-term treatment, it may be a low cost therapeutic option used in specific short-term situations.
Trial registration: NCT03608839 (http://www.clinicaltrials.gov).
Keywords: intravitreal dexamethasone solution, short-term treatment, diabetic macular edema, pseudophakic patients
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]